| Literature DB >> 19635508 |
Say Li Kong1, Paul Chui, Bing Lim, Manuel Salto-Tellez.
Abstract
Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury. It is a response to various diseases of variable etiology, including SARS-CoV infection. To date, a comprehensive study of the genomic physiopathology of ARDS (and SARS) is lacking, primarily due to the difficulty of finding suitable materials to study the disease process at a tissue level (instead of blood, sputa or swaps). Hereby we attempt to provide such study by analyzing autopsy lung samples from patient who died of SARS and showed different degrees of severity of the pulmonary involvement. We performed real-time quantitative PCR analysis of 107 genes with functional roles in inflammation, coagulation, fibrosis and apoptosis; some key genes were confirmed at a protein expression level by immunohistochemistry and correlated to the degree of morphological severity present in the individual samples analyzed. Significant expression levels were identified for ANPEP (a receptor for CoV), as well as inhibition of the STAT1 pathway, IFNs production and CXCL10 (a T-cell recruiter). Other genes unassociated to date with ARDS/SARS include C1Qb, C5R1, CASP3, CASP9, CD14, CD68, FGF7, HLA-DRA, IGF1, IRF3, MALAT-1, MSR1, NFIL3, SLPI, USP33, CLC, GBP1 and TAC1. As a result, we proposed to therapeutically target some of these genes with compounds such as ANPEP inhibitors, SLPI and dexamethasone. Ultimately, this study may serve as a model for future, tissue-based analyses of fibroinflammatory conditions affecting the lung.Entities:
Mesh:
Year: 2009 PMID: 19635508 PMCID: PMC7114434 DOI: 10.1016/j.virusres.2009.07.014
Source DB: PubMed Journal: Virus Res ISSN: 0168-1702 Impact factor: 3.303
Clinical information of patients died of SARS-CoV infection.
| Patient | |||||||
|---|---|---|---|---|---|---|---|
| I | II | III | IV | V | VI | VII | |
| Age | 67 | 43 | 38 | 64 | 50 | 29 | 39 |
| Gender | Female | Male | Male | Male | Male | Female | Male |
| Symptoms | Fever, dry cough | Fever | Fever with mild myalgia and chills | Fever | Fever, dry cough, myalgia, malaise | Fever, malaise, shortness of breath, dry cough | Fever, dry cough |
| Diagnosis | Diffuse alveolar damage | Early phase diffuse alveolar damage | Diffuse pneumonia | Bilateral infiltrates, progressive sepsis | Multiorgan failure secondary to SARS | Developed sepsism, multiorgan failure, bleeding tendencies | Atypical Pneumonia; acute myocardial infarct; septic shock |
| Treatment | Died at home | Collapsed when admitted | Cortico-steroid given | No cortico-steroid given | Cortico-steroid given | Cortico-steroid given | Cortico-steroid given |
| Mechanical ventilation | No | No | Yes | Yes | Yes | Yes | Yes |
Fig. 1(a–h, j) Representation of histological appearances (H&E stained) for lung tissue samples collected in this study. All these samples were representative of the spectrum of changes in ARDS, showing a clear disease progression from early stage leading to the end-stage lung fibrosis. The morphological description of these samples is shown in Table 1.
The histological description for FFPE lung samples used in this study.
| Patient | Sample | Stage | Grade | Autopsy description |
|---|---|---|---|---|
| I | A | Early | 1 | Alveolar walls with obvious congestion. Alveolar spaces with early membranes (refer |
| II | B | Early | 2 | Alveolar spaces with early membranes. Obvious bacterial overgrowth. |
| III | C | Early | 3 | Alveolar spaces with some inflammation and membranes. Early intravascular thrombus formation (refer |
| III | D | Early | 4 | Alveolar spaces with some inflammation and membranes (more than in previous). No intravascular thrombus formation. |
| IV | E | Early | 5 | Alveolar spaces with some inflammation and membranes (more than in previous). No intravascular thrombus formation ( |
| IV | F | Early | 6 | Membranes (more than previously, |
| V | G | Late | 7 | Some areas relatively unaffected, other with BOOP-like appearance ( |
| VI | H | Late | 8.1 | Intra-alveolar fibrosis and consolidation ( |
| VI | I | Late | 8.2 | Intra-alveolar fibrosis and consolidation, with giant cells. Early thrombus formation. |
| VII | J | Late | 9 | Extensive intra-alveolar fibrosis and consolidation. Early thrombus formation. |
| V | K | Late | 10 | Increased fibrosis and consolidation (refer |
| VII | L | Late | 11 | Fully established fibrosis and consolidation. |
Fig. 2The characterization of the list of 107 genes studied.
List of genes that are over-expressed (mean expression level ≥1.5) in SARS-CoV infected lung tissue samples. All real-time qPCR results were expressed as fold changes in mRNA expression of patient samples with respect to the control samples and were normalized to the expression of the housekeeping gene β-actin.
| No. | Over-expressed gene | Mean expression level for early stage | Mean expression level for late stage |
|---|---|---|---|
| 1 | BPI | 159.68 | 11557.50 |
| 2 | ACE2 | 387.16 | 2805.44 |
| 3 | TAC1 | 1.04 | 765.88 |
| 4 | CASP3 | 18.49 | 520.09 |
| 5 | CEACAM8 | 13.67 | 274.43 |
| 6 | DEFA4 | 41.77 | 147.51 |
| 7 | IL10 | 9.37 | 121.10 |
| 8 | CCL3 | 7.84 | 76.59 |
| 9 | S100A8 | 2.38 | 73.41 |
| 10 | HLA-A | 1.22 | 60.59 |
| 11 | PPBP | 4.53 | 57.73 |
| 12 | CCL27 | 1.00 | 49.40 |
| 13 | LILRA3 | 6.50 | 43.80 |
| 14 | MICB | 16.79 | 38.89 |
| 15 | ANPEP | 2.74 | 36.04 |
| 16 | MNDA | 0.60 | 34.09 |
| 17 | USP | 8.94 | 32.79 |
| 18 | ITGAM | 4.88 | 32.36 |
| 19 | CXCL9 | 49.52 | 30.22 |
| 20 | IL1B | 2.25 | 29.50 |
| 21 | C1QB | 4.68 | 28.38 |
| 22 | ICAM1 | 4.56 | 26.57 |
| 23 | MAD | 10.93 | 26.33 |
| 24 | CD69 | 1.96 | 25.76 |
| 25 | CXCL10 | 164.93 | 25.57 |
| 26 | IMPA2 | 4.50 | 24.09 |
| 27 | IL1R1 | 3.22 | 21.94 |
| 28 | GBP | 132.93 | 21.58 |
| 29 | CD68 | 1.31 | 18.48 |
| 30 | EDN1 | 16.08 | 16.99 |
| 31 | IL8 | 0.55 | 16.50 |
| 32 | CSF2RA | 0.45 | 16.47 |
| 33 | CREBBP | 5.98 | 16.35 |
| 34 | FGF7 | 3.28 | 16.23 |
| 35 | SMAD | 8.83 | 15.34 |
| 36 | MSR1 | 2.46 | 15.21 |
| 37 | IL6 | 4.59 | 14.71 |
| 38 | CD22 | 1.36 | 14.65 |
| 39 | PECAM1 | 2.60 | 14.10 |
| 40 | MALAT-1 | 4.15 | 12.27 |
| 41 | BCAP29 | 7.14 | 11.87 |
| 42 | ITGA2B | 152.46 | 11.65 |
| 43 | LILRA2 | 5.12 | 11.53 |
| 44 | RAB31 | 1.32 | 11.13 |
| 45 | B2M | 5.28 | 10.93 |
| 46 | AREG | 2.17 | 9.79 |
| 47 | RPGR | 3.33 | 9.47 |
| 48 | IFNA6 | 2.36 | 8.92 |
| 49 | NFIL3 | 1.50 | 8.36 |
| 50 | CD4 | 0.87 | 8.31 |
| 51 | LTB4R | 2.93 | 8.27 |
| 52 | CCL28 | 4.10 | 8.14 |
| 53 | VEGF | 3.05 | 8.13 |
| 54 | CXCL2 | 0.90 | 7.76 |
| 55 | NFKBIA | 2.93 | 7.57 |
| 56 | IGF1 | 0.72 | 7.16 |
| 58 | ATP1B1 | 1.74 | 7.06 |
| 59 | NCF1 | 2.24 | 6.87 |
| 60 | CASP9 | 0.33 | 6.75 |
| 61 | KIAA0720 | 2.06 | 6.74 |
| 62 | IRF3 | 0.73 | 6.71 |
| 63 | CD14 | 0.83 | 6.70 |
| 64 | TFPI | 3.90 | 6.53 |
| 65 | DTR | 4.82 | 6.52 |
| 66 | CD9 | 1.43 | 5.59 |
| 67 | C4B | 2.60 | 5.37 |
| 68 | HIST2H2AA | 2.69 | 5.06 |
| 69 | SLPI | 0.49 | 4.32 |
| 70 | TNFSF5 | 1.73 | 4.00 |
| 71 | CSF1 | 2.91 | 3.97 |
| 72 | C3AR1 | 1.43 | 3.92 |
| 73 | LTB | 1.12 | 3.86 |
| 74 | HLA-DRA | 0.73 | 3.71 |
| 75 | PTAFR | 1.12 | 3.60 |
| 76 | STAT1 | 9.86 | 3.43 |
| 77 | ICAM2 | 1.84 | 3.41 |
| 78 | C5R1 | 0.29 | 3.36 |
| 79 | PIK3CB | 1.65 | 3.33 |
| 80 | TLR2 | 0.29 | 2.98 |
| 81 | CD3Z | 3.02 | 2.86 |
| 82 | EGR1 | 0.94 | 2.72 |
| 83 | CD8A | 0.74 | 2.39 |
| 84 | CCL2 | 2.16 | 2.31 |
| 85 | TNFRSF1A | 0.78 | 2.25 |
| 87 | NR2F2 | 1.28 | 2.10 |
| 86 | EGR2 | 1.22 | 2.10 |
| 88 | IFNB1 | 0.82 | 1.75 |
| 89 | IFNA1 | 2.08 | 1.52 |
| 90 | HP | 0.14 | 1.51 |
| 91 | IFNG | 1.74 | 1.05 |
| 92 | CLC | 12.29 | 1.00 |
Fig. 3Expression profiles of the top 5 genes that are significantly up-regulated in the severity progression of SARS-CoV infections (open bars represent early disease stage samples; filled bars represent late disease stage samples).
Fig. 4Expression profiles of the top 5 genes that are significantly down-regulated in the severity progression of SARS-CoV infections (open bars represent early disease stage samples; filled bars represent late disease stage samples).
SAM and Mann–Whitney analysis were performed to identify genes that are significantly up- or down-regulated in the progression of disease.
| Gene | Mann–Whitney test | SAM test | Mean early expression level | Mean late expression level | ||
|---|---|---|---|---|---|---|
| Score( | ||||||
| (a) Up-regulated | ||||||
| BPI | −2.934 | 0.002 | 2.175 | 4.856 | 159.68 | 11557.50 |
| CASP3 | −2.082 | 0.041 | N.A. | N.A. | 18.49 | 520.09 |
| CEACAM8 | −2.562 | 0.009 | 1.794 | 4.856 | 13.67 | 274.43 |
| S100A8 | −2.082 | 0.041 | 1.845 | 4.856 | 2.38 | 73.41 |
| ANPEP | −2.082 | 0.041 | 3.617 | 4.856 | 2.74 | 36.04 |
| USP | N.A. | N.A. | 0.884 | 0 | 8.94 | 32.79 |
| C1QB | −1.761 | 0.093 | 1.999 | 4.856 | 4.68 | 28.38 |
| IL1R1 | −2.402 | 0.015 | 1.910 | 4.856 | 3.22 | 21.94 |
| CD68 | −2.562 | 0.009 | 2.130 | 4.856 | 1.31 | 18.48 |
| IL8 | −2.082 | 0.041 | 1.657 | 4.856 | 0.55 | 16.50 |
| FGF7 | −1.761 | 0.093 | 2.165 | 4.856 | 3.28 | 16.23 |
| MSR1 | −2.242 | 0.026 | 1.997 | 4.856 | 2.46 | 15.21 |
| MALAT-1 | N.A. | N.A. | 1.061 | 0 | 4.15 | 12.27 |
| RAB31 | −2.082 | 0.041 | 2.403 | 4.856 | 1.32 | 11.13 |
| NFIL3 | −2.882 | 0.002 | 2.934 | 4.856 | 1.50 | 8.36 |
| CD4 | −2.402 | 0.015 | 2.578 | 4.856 | 0.87 | 8.31 |
| IGF1 | −2.882 | 0.002 | 4.448 | 4.856 | 0.72 | 7.16 |
| CASP9 | −2.242 | 0.026 | 1.768 | 4.856 | 0.33 | 6.75 |
| IRF3 | −2.882 | 0.002 | 2.635 | 4.856 | 0.73 | 6.71 |
| CD14 | −2.562 | 0.009 | 3.749 | 4.856 | 0.83 | 6.70 |
| SLPI | −2.242 | 0.026 | 1.863 | 4.856 | 0.49 | 4.32 |
| TNFSF5 | N.A. | N.A. | 0.884 | 0 | 1.73 | 4.00 |
| HLA-DRA | −2.562 | 0.009 | 2.003 | 4.856 | 0.73 | 3.71 |
| C5R1 | −2.082 | 0.041 | 1.723 | 4.856 | 0.29 | 3.36 |
| TLR2 | −2.402 | 0.015 | 2.356 | 4.856 | 0.29 | 2.98 |
| HP | −1.684 | 0.093 | 1.719 | 4.856 | 0.14 | 1.51 |
| (b) Down-regulated | ||||||
| CXCL10 | 2.402 | 0.015 | N.A. | N.A. | 164.93 | 25.57 |
| GBP | N.A. | N.A. | −1.061 | 0 | 132.93 | 21.58 |
| ITGA2B | 2.201 | 0.026 | N.A. | N.A. | 152.46 | 11.65 |
| STAT1 | N.A. | N.A. | −0.884 | 0 | 9.86 | 3.43 |
| CLC | 3.077 | 0.002 | N.A. | N.A. | 12.29 | 1.00 |
Statistical significance: p < 0.05 by Mann–Whitney test; q-value < 5% by SAM method. N.A. = not available.
Fig. 5List of genes involved in immunological response against viral or bacterial infection (data were analyzed through the use of Ingenuity® Pathway Analysis).
Fig. 6The IHC results demonstrated the correlation between gene and protein expression profiles in SARS-CoV infected patients.
Fig. 7Hypothesized pathogenesis model for SARS-CoV infections.